

Genome-wide association study identifies a *PSMD3* variant associated with neutropenia in interferon-based therapy for chronic hepatitis C

Etsuko Iio · Kentaro Matsuura · Nao Nishida · Shinya Maekawa · Nobuyuki Enomoto · Mina Nakagawa · Naoya Sakamoto · Hiroshi Yatsunami · Masayuki Kurosaki · Namiki Izumi · Yoichi Hiasa · Naohiko Masaki · Tatsuya Ide · Keisuke Hino · Akihiro Tamori · Masao Honda · Shuichi Kaneko · Satoshi Mochida · Hideyuki Nomura · Shuhei Nishiguchi · Chiaki Okuse · Yoshito Itoh · Hitoshi Yoshiji · Isao Sakaida · Kazuhide Yamamoto · Hisayoshi Watanabe · Shuhei Hige · Akihiro Matsumoto · Eiji Tanaka · Katsushi Tokunaga · Yasuhito Tanaka

Received: 2 October 2014 / Accepted: 8 December 2014
© Springer-Verlag Berlin Heidelberg 2014

Abstract Cytopenia during interferon-based (IFN-based) therapy for chronic hepatitis C (CHC) often necessitates reduction of doses of drugs and premature withdrawal from therapy resulting in poor response to treatment. To identify genetic variants associated with IFN-induced neutropenia, we conducted a genome-wide association study (GWAS) in 416 Japanese CHC patients receiving IFN-based therapy. Based on the results, we selected 192 candidate single nucleotide polymorphisms

(SNPs) to carry out a replication analysis in an independent set of 404 subjects. The SNP rs2305482, located in the intron region of the *PSMD3* gene on chromosome 17, showed a strong association when the results of GWAS and the replication stage were combined (OR = 2.18, $P = 3.05 \times 10^{-7}$ in the allele frequency model). Logistic regression analysis showed that rs2305482 CC and neutrophil count at baseline were independent predictive factors for IFN-induced neutropenia (OR = 2.497, $P = 0.0072$ and OR = 0.998, $P < 0.0001$, respectively). Furthermore, rs2305482 genotype was associated with the doses of pegylated interferon (PEG-IFN) that could be tolerated in hepatitis C virus genotype 1-infected patients treated with PEG-IFN plus ribavirin, but not with treatment efficacy. Our results suggest that genetic

E. Iio and K. Matsuura equally contributed to this work (shared first authorship).

Electronic supplementary material The online version of this article (doi:10.1007/s00439-014-1520-7) contains supplementary material, which is available to authorized users.

E. Iio · K. Matsuura · Y. Tanaka (✉)
Department of Virology and Liver Unit, Nagoya City University
Graduate School of Medical Sciences, Kawasumi, Mizuho,
Nagoya 467-8601, Japan
e-mail: ytanaka@med.nagoya-cu.ac.jp

E. Iio · K. Matsuura
Department of Gastroenterology and Metabolism, Nagoya
City University Graduate School of Medical Sciences,
Nagoya 467-8601, Japan

N. Nishida · N. Masaki
The Research Center for Hepatitis and Immunology, National
Center for Global Health and Medicine, Ichikawa 272-8516,
Japan

N. Nishida · K. Tokunaga
Department of Human Genetics, Graduate School of Medicine,
The University of Tokyo, Tokyo 113-0033, Japan

S. Maekawa · N. Enomoto
First Department of Internal Medicine, University of Yamanashi,
Chuo 409-3898, Japan

M. Nakagawa · N. Sakamoto
Department of Gastroenterology and Hepatology, Tokyo Medical
and Dental University, Tokyo 113-0034, Japan

N. Sakamoto · S. Hige
Department of Internal Medicine, Hokkaido University Graduate
School of Medicine, Sapporo 060-0814, Japan

H. Yatsunami
Clinical Research Center, National Nagasaki Medical Center,
Omura 856-8562, Japan

M. Kurosaki · N. Izumi
Division of Gastroenterology and Hepatology, Musashino Red
Cross Hospital, Musashino 180-0023, Japan

testing for this variant might be useful for establishing personalized drug dosing in order to minimize drug-induced adverse events.

Introduction

Chronic hepatitis C virus (HCV) infection is a significant risk factor for progressive liver fibrosis and hepatocellular carcinoma. Antiviral treatment improves the natural course in chronic hepatitis C (CHC) (George et al. 2009; Yoshida et al. 2004). Newly-developed treatments involving direct-acting antivirals (DAAs), including nonstructural (NS) 3/4A protease inhibitors have shown promising outcomes in combination with pegylated interferon (PEG-IFN) plus ribavirin (RBV) in several clinical trials. Thus, >70 % of patients infected with HCV genotype 1 are reported to achieve sustained virological responses (SVR) (Jacobson et al. 2011; Poordad et al. 2012; Zeuzem et al. 2011). Furthermore, interferon-free (IFN-free) therapies are expected to be useful especially in IFN-resistant patients and may become the standard of care in the near future. However, IFN-based regimens have been standard-of-care therapies over the last couple of decades.

IFN-based therapies are associated with various adverse effects. Cytopenia is common due to bone marrow suppression caused by IFN or DAA and hemolysis by RBV. This is particularly the case in patients with advanced hepatic fibrosis, but can sometimes also occur in those with mild fibrosis. This then often necessitates dose reduction or premature withdrawal from therapy, resulting in poor response to treatment. For instance, it was reported that rates of viral clearance were

significantly reduced in patients who could not be maintained on at least 80 % of their drug doses for the duration of PEG-IFN/RBV therapy (McHutchison et al. 2002). Therefore, pre-treatment prediction of possible adverse effects in order to avoid them and undergo therapy safely is desirable.

Recent genome-wide association studies (GWASs) have identified two important host genetic variants influencing CHC treatment: (1) single nucleotide polymorphisms (SNPs) near the interleukin-28B (*IL28B*) gene, which are strongly associated with response to therapy for chronic HCV genotype 1 infection (Ge et al. 2009; Suppiah et al. 2009; Tanaka et al. 2009), and (2) SNPs in the inosine triphosphatase (*ITPA*) gene, which accurately predict RBV-induced anemia in European–American (Fellay et al. 2010) and Japanese population (Ochi et al. 2010). We validated the association between this *ITPA* genetic variant and RBV-induced anemia (Sakamoto et al. 2010), and reported that the *ITPA* genotype affects the tolerated doses of RBV and treatment response in a stratified group (Kurosaki et al. 2011; Matsuura et al. 2014). Additionally, our GWAS showed that *DDR1/ITPA* variants are strongly associated with IFN-induced thrombocytopenia as well as anemia during PEG-IFN/RBV therapy (Tanaka et al. 2011). Thompson et al. (2012) also reported that the *ITPA* genetic variant was associated with anemia and thrombocytopenia during PEG-IFN/RBV therapy. However they identified no genetic determinants of IFN-induced neutropenia at the level of genome-wide significance by their GWAS in populations of European Americans, African Americans and Hispanics.

Hence, to identify genetic variants associated with IFN-induced neutropenia, we conducted a GWAS in Japanese CHC patients.

Y. Hiasa

Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine, Toon 791-0295, Japan

T. Ide

Division of Gastroenterology, Department of Medicine, Kurume University, Kurume 830-0011, Japan

K. Hino

Department of Hepatology and Pancreatology, Kawasaki Medical School, Kurashiki 701-0114, Japan

A. Tamori

Department of Hepatology, Osaka City Graduate School of Medicine, Osaka 545-8585, Japan

M. Honda · S. Kaneko

Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa 920-0934, Japan

S. Mochida

Division of Gastroenterology and Hepatology, Internal Medicine, Saitama Medical University, Iruma 350-0495, Japan

H. Nomura

The Center for Liver Disease, Shin-Kokura Hospital, Kitakyushu 803-8505, Japan

S. Nishiguchi

Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya 663-8131, Japan

C. Okuse

Department of Gastroenterology and Hepatology, St. Marianna University School of Medicine, Kawasaki 216-8511, Japan

Y. Itoh

Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto 602-0841, Japan

H. Yoshiji

Third Department of Internal Medicine, Nara Medical University, Kashihara 634-8522, Japan

I. Sakaida

Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube 755-8505, Japan

Materials and methods

Patients

From 2007 to 2012, samples for the GWAS were obtained from 416 CHC patients who were treated at 22 hospitals (liver units with hepatologists) throughout Japan. In the following stage of replication analysis, samples were collected in an independent set of 404 Japanese CHC patients. Most patients were treated with PEG-IFN- α 2b (1.5 μ g/kg body weight subcutaneously once a week) or PEG-IFN- α 2a (180 μ g once a week) plus RBV (600–1,000 mg daily according to body weight) for 48 weeks for HCV genotype 1 and 24 weeks for genotype 2. Treatment duration was extended in some patients up to 72 weeks for genotype 1 and 48 weeks for genotype 2 according to physicians' preferences. Other patients were treated with PEG-IFN- α 2a or IFN monotherapy, or IFN- α 2b plus RBV in standard doses of the regimens. The doses of drugs were reduced according to the recommendations on the package inserts or the clinical conditions of the individual patients. Erythropoietin or other growth factors were not given. Patients chronically infected with hepatitis B virus or human immunodeficiency virus, or with other causes of liver disease such as autoimmune hepatitis and primary biliary cirrhosis, were excluded from this study. Written informed consent was obtained from all individual participants in this study and the study protocol conformed to the ethics guidelines of the Declaration of Helsinki and was approved by the institutional ethics review committees.

Inclusion criteria of neutropenia

In the initial stage of GWAS, we defined the inclusion criteria of the case group as minimum neutrophil counts of $<750/\text{mm}^3$ at week 2 or 4 during IFN-based therapy, since the dose reduction of IFN is recommended at those levels on the package inserts. Thereafter we did it as minimum

neutrophil counts of $<600/\text{mm}^3$ at week 2 or 4 in the following GWAS and the replication stages.

SNP genotyping and data cleaning

We conducted two stages of GWAS using the Affymetrix Genome-Wide Human SNP Array 6.0 (Affymetrix, Inc. Santa Clara, CA) according to the manufacturer's instructions. The cut-off value was calculated to maximize the difference, which was also close to median change. At GWAS, the average overall call rate of patients in the case and the control group reached 98.66 and 98.79 %, respectively. We then applied the following thresholds for SNP quality control (QC) in data cleaning: SNP call rate ≥ 95 % for all samples, minor allele frequency (MAF) ≥ 1 % for all samples. A total of 601,578 SNPs on autosomal chromosomes passed the QC filters and were used for association analysis. All cluster plots of SNPs showing $P < 0.0001$ in association analyses by comparing allele frequencies in both groups were checked by visual inspection and SNPs with ambiguous genotype calls were excluded. In the replication study, the genotyping of 192 candidate SNPs in an independent set of 404 Japanese HCV-infected patients was carried out using the DigiTag2 assay (Nishida et al. 2007). Successfully genotyped SNPs in the replication analysis had a >95 % call rate, and cleared Hardy–Weinberg equilibrium (HWE) $P \geq 0.001$. One SNP could not be genotyped, and hence we obtained data on 191 SNPs including rs9915252. Three SNPs, rs4794822, rs3907022, and rs3859192 located around the proteasome 26S subunits non-ATPase 3 (*PSMD3*) gene and rs8099917 near the *IL28B* gene were genotyped by TaqMan SNP Genotyping Assays (Applied Biosystems, Carlsbad, CA) following the manufacturer's protocol.

Laboratory and histological tests

Blood samples were obtained at baseline and at appropriate periods after the start of therapy and for hematologic tests, blood chemistry, and HCV RNA. Fibrosis was evaluated on a scale of 0–4 according to the METAVIR scoring system. The SVR was defined as an undetectable HCV RNA level by Roche COBAS Amplicor HCV Monitor test, v.2.0 (Roche Molecular Diagnostics, Pleasanton, CA) with a lower detection limit of 50 IU/ml or Roche COBAS AmpliPrep/COBAS TaqMan HCV assay (Roche Molecular Diagnostics, Pleasanton, CA) with a lower detection limit of 15 IU/ml 24 weeks after the completion of therapy. Serum granulocyte colony-stimulating factor (G-CSF) levels were analyzed using Human G-CSF Quantikine ELISA Kit (R&D Systems, Inc., Minneapolis, MN).

K. Yamamoto

Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-0914, Japan

H. Watanabe

Department of Gastroenterology, Yamagata University Faculty of Medicine, Yamagata 990-9585, Japan

S. Hige

Department of Gastroenterology, Sapporo Kosei General Hospital, Sapporo 060-0033, Japan

A. Matsumoto · E. Tanaka

Department of Medicine, Shinshu University School of Medicine, Matsumoto 390-8621, Japan

Expression quantitative trait locus analysis

Expression quantitative trait locus analysis (eQTL) was conducted using the web-based tool, Genevar (<http://www.sanger.ac.uk/resources/software/genevar>) (Yang et al. 2010). We evaluated the correlations between rs2305482 genotypes and the expression of transcripts of *PSMD3* or colony-stimulating factor 3 (*CSF3*) by the Spearman's rank correlation coefficient.

Statistical analysis

In the GWAS and the replication stages, the observed association between a SNP and neutropenia induced by IFN-based therapy was assessed by the Chi square test with a two-by-two contingency table in three genetic models: the allele frequency model, the dominant-effect model and the recessive-effect model. Significance levels after Bonferroni correction for multiple testing were $P = 8.31 \times 10^{-8}$ (0.05/601,578) in the GWAS stage and $P = 2.62 \times 10^{-4}$ (0.05/191) in the replication stage. Categorical variables were compared between groups by the Chi square test, and non-categorical variables by the Student's *t* test or the Mann–Whitney *U* test. Multivariate logistic regression analysis with stepwise forward selection was performed with $P < 0.05$ in univariate analysis as the criteria for model inclusion. To evaluate the discriminatory ability of neutrophil counts at baseline to predict neutropenia during IFN-based therapy, receiver operating characteristic curve (ROC) curve analysis was conducted. Changes of serum G-CSF levels from baseline to the period with neutropenia during IFN-based therapy were compared by the repeated measure analysis of variance

(ANOVA). Correlations between neutrophil counts and serum G-CSF levels were analyzed using Pearson's correlation coefficient test. $P < 0.05$ was considered significant in all tests.

Results

Genetic variants associated with IFN-induced neutropenia

We conducted two stages of GWAS by changing the terms of neutrophil counts, followed by the replication analysis (Fig. 1). The characteristics of the patients in each group for the GWAS and the replication stage are summarized in Table 1. At the first stage of GWAS (GWAS-1st), we genotyped 416 Japanese CHC patients with minimum neutrophil counts of $<750/\text{mm}^3$ (Case-G1, $n = 114$) and $\geq 1,000/\text{mm}^3$ (Control-G, $n = 302$) at week 2 or 4 during IFN-based therapy. Here there may still be mixed with undesirable samples that should be removed from the case group. Therefore, we designed and carried out the second stage of GWAS (GWAS-2nd) comparing the patients with more severe neutropenia to the control group: in patients with minimum neutrophil counts of $<600/\text{mm}^3$ (Case-G2, $n = 50$) and $\geq 1,000/\text{mm}^3$ (Control-G, $n = 302$) at week 2 or 4 using the same samples as used in GWAS-1st. Supplementary Fig. 1 shows a genome-wide view of the single-point association data based on allele frequencies in GWAS-1st and GWAS-2nd. No association between SNPs and IFN-induced neutropenia reached a genome-wide level of significance [Bonferroni criterion $P < 8.31 \times 10^{-8}$ (0.05/601,578)]. Therefore, we selected the candidate SNPs principally

Fig. 1 Outline of the study design. *Neut* neutrophil counts, *SNP* single nucleotide polymorphism, *QC* quality control, *OR* odds ratio




Table 1 Clinical characteristics of patients in GWAS and the replication study

	GWAS			Replication study	
	Case-G1 (<i>n</i> = 114)	Case-G2 (<i>n</i> = 50)	Control-G (<i>n</i> = 302)	Case-R (<i>n</i> = 50)	Control-R (<i>n</i> = 354)
At baseline					
Gender, male/female	48/66	21/29	170/132	24/26	208/146
Age, years	57.9 (8.7)	57.1 (8.3)	57.2 (11.2)	59.1 (10.2)	56.7 (9.6)
Neutrophil count, /mm ³	1,800 (777)	1,662 (897)	2,750 (984)	1,570 (552)	2,724 (985)
Hemoglobin, g/dL	13.6 (1.3)	13.5 (1.3)	14.2 (1.5)	13.6 (1.6)	14.3 (1.5)
Platelet count, ×10 ⁹ /L	141 (42)	132 (46)	164 (54)	140 (47)	162 (60)
ALT, IU/L	82.9 (88.6)	70.4 (53.1)	81.5 (77.9)	87.8 (82.7)	85.2 (71.1)
HCV genotype, 1/2/ND	95/18/1	40/10/0	250/51/1	45/5/0	277/77/0
HCV RNA, log IU/mL	5.9 (0.8)	5.9 (1.0)	6.1 (0.8)	6.1 (0.9)	6.1 (0.8)
Liver fibrosis, F0-2/F3-4/ND	62/22/30	25/10/15	168/70/64	21/6/23	229/87/38
rs8099917, TT/TG + GG/ND	74/39/1	35/15/0	189/109/4	31/17/2	278/70/6
Regimen					
PEG-IFN + RBV/IFN + RBV/PEG-IFN/IFN mono	112/0/0/2	48/0/0/2	277/9/9/7	44/4/2/0	351/0/3/0
At week 4					
Neutrophil count, /mm ³	606 (126)	496 (104)	1,551 (501)	501 (89)	1,533 (484)

Data are expressed as number for categorical data or the mean (standard deviation) for non-categorical data

GWAS genome-wide association study, ALT alanine transaminase, ND not determined, PEG-IFN pegylated interferon, IFN mono, interferon monotherapy, RBV ribavirin

by comparing between GWAS-1st and GWAS-2nd as follows. There were 6,315 and 5,736 SNPs with odds ratios (ORs) <0.7 or >1.5 at GWAS-1st and GWAS-2nd, respectively. Of these, the ORs of 135 SNPs were more notable at GWAS-2nd than at GWAS-1st. In addition to the 135 SNPs, we selected 15 and 33 SNPs with $P < 10^{-4}$ at GWAS-1st and GWAS-2nd, and added 9 SNPs which are located around the candidate genetic regions identified by the GWAS stage and are non-synonymous or related to diseases in previous reports. Consequently, we carried out the replication analysis focusing on this total of 192 SNPs.

In the subsequent replication analysis, we carried out genotyping of the 192 candidate SNPs in an independent set of 404 Japanese HCV-infected patients with minimum neutrophil counts of <600/mm³ (Case-R, *n* = 50) and ≥1,000/mm³ (Control-R, *n* = 354) at week 2 or 4 during IFN-based therapy (Table 1; Fig. 1). The results in the replication stage combined with GWAS-2nd are shown in Supplementary Table 1. Several SNPs such as rs11743919 and rs2457840 showed strong associations with low *P* value, however, the MAF of them were <5 %. In general, low frequent SNPs tend to show unsettled associations, especially in statistical analysis with small number of samples. Therefore, we excluded these SNPs from the final candidates. Consequently, we determined the SNP rs2305482, located in the intron of *PSMD3* gene on chromosome 17, as the most promising candidate, which showed a strong

association with IFN-induced neutropenia in the combined results of GWAS-2nd and the replication stage (OR = 2.18; 95 % CI = 1.61–2.96, $P = 3.05 \times 10^{-7}$ in the allele frequency model) (Table 2).

Association of SNPs located in *PSMD3-CSF3* with neutropenia

A previous GWAS showed that rs4794822 located between the *PSMD3* and *CSF3* genes was associated with neutrophil counts in Japanese patients including 14 different disease groups (Okada et al. 2010). As shown in Fig. 2, rs4794822 is in strong linkage disequilibrium (LD) with rs2305482 which we identified in the present study. Thus, the pairwise LD (r^2) in the HapMap JPT: Japanese in Tokyo, Japan, is 0.66. Because the SNP rs4794822 is not included in the Affymetrix Genome-Wide Human SNP Array 6.0, we additionally genotyped it together with three other SNPs (rs9915252, rs3859192 and rs3907022) located in the same LD block around the *PSMD3* gene (Fig. 2). The allele frequency of each SNP was compared between patients with minimum neutrophil counts of <600/mm³ (Case-G2 + R: Case-G2 plus Case-R, *n* = 100) and ≥1,000/mm³ (Control-G + R: Control-G plus Control-R, *n* = 656) at week 2 or 4 during IFN-based therapy. This showed that, rs4794822 was also strongly associated with neutropenia during IFN-based therapy (OR = 2.24; 95 % CI = 1.63–3.07, $P = 3.63 \times 10^{-7}$ in the allele frequency model) (Table 3).

Table 2 SNP associated with interferon-induced neutropenia

dbSNP rsID	Nearest gene	Risk allele	Allele (1/2)	Stage	Case		Control		OR ^a (95 % CI)	P value ^b		
					11	12	11	12				
rs2305482	<i>PSMD3</i>	C	C/A	GWAS-1st	23 (20.4)	52 (46.0)	38 (33.6)	26 (8.6)	143 (47.4)	133 (44.0)	1.61 (1.17–2.20)	2.95 × 10 ⁻³
				GWAS-2nd	12 (24.5)	28 (57.1)	9 (18.4)	26 (8.6)	143 (47.4)	133 (44.0)	2.37 (1.54–3.65)	6.47 × 10 ⁻⁵
				Replication	12 (24.4)	20 (40.8)	17 (34.7)	33 (9.5)	136 (39.1)	179 (51.4)	1.99 (1.30–3.06)	1.46 × 10 ⁻³
				Combined ^c	24 (24.5)	48 (49.0)	26 (26.5)	59 (9.1)	279 (42.9)	312 (48.0)	2.18 (1.61–2.96)	3.05 × 10 ⁻⁷

Data of allele distribution represent number (%). Data of subjects whose genotypes were not determined were excluded

SNP single nucleotide polymorphism

^a Odds ratio for the allele frequency model

^b P value by the Chi square test for the allele frequency model

^c Allele distributions in GWAS-2nd and replication were combined

Predictive factors for IFN-induced neutropenia

The following analyses were carried out for rs2305482 and rs4794822 using the subjects in Case-G2 + R and Control-G + R. Neutrophil counts at baseline correlated with rs2305482 and rs4794822 genotypes (Supplementary Fig. 2), and strongly affected IFN-induced neutropenia as shown by ROC analysis (area under the curve = 0.860) (Supplementary Fig. 3). Furthermore, gender, hemoglobin level, and platelet count at baseline were also significantly associated with IFN-induced neutropenia by univariate analysis (Table 4). Therefore, we analyzed pretreatment predictive factors for IFN-induced neutropenia in logistic regression models that included the following variables: gender, neutrophil count, platelet count, and rs2305482 or rs4794822 genotypes. In addition to neutrophil count, rs2305482 CC was an independent predictive factor for IFN-induced neutropenia (OR = 2.497; 95 % CI = 1.281–4.864, $P = 0.0072$) (Table 5) as was rs4794822 CC (OR = 2.272; 95 % CI = 1.337–3.861, $P = 0.0024$) (Supplementary Table 2).

Impact of *PSMD3-CSF3* SNPs on tolerated drug doses and treatment efficacy

To evaluate the impact of *PSMD3-CSF3* SNPs on doses of drugs given, and on treatment efficacy, we selected 380 HCV genotype 1-infected patients treated with PEG-IFN/RBV for 48 weeks. They were selected as having information available on the doses of PEG-IFN/RBV that they had received (Supplementary Table 3). It was reported that rates of viral clearance were significantly reduced in patients who could not be maintained on at least 80 % of their drug doses for the duration of PEG-IFN/RBV therapy (McHutchison et al. 2002). In reference to this result, we stratified the patients into three groups according to the doses of PEG-IFN or RBV administered, as follows: <60 %, ≥60 to <80 %, ≥80 % of the planned doses for 48 weeks. The proportion of patients in the <60 % group for PEG-IFN was significantly higher in patients possessing rs2305482 CC than in those with AA/AC ($P = 0.005$), whereas there was no association for RBV (Fig. 3). The same results were found in the analysis of rs4794822 (Supplementary Fig. 4). However, the univariate analysis of pretreatment factors associated with SVR showed that there was no association between SVR and rs2305482 or rs4794822 genotypes (Supplementary Table 3).

Candidate SNP-gene association analysis in IFN-induced neutropenia

To investigate whether the SNPs associated with neutropenia affect the expression of nearby genes, we conducted




Fig. 2 Position on chromosome and pairwise linkage disequilibrium (r^2) diagrams in the HapMap JPT around the *PSMD3-CSF3* locus

an eQTL analysis. The C allele of rs2305482, a risk for neutropenia, was associated with higher expression levels of *PSMD3* in the populations of LWK: Luhya in Webuye, Kenya ($\rho = 0.30$, $P = 0.006$), and MEX: Mexican ancestry in Los Angeles, California ($\rho = 0.36$, $P = 0.015$) (Supplementary Fig. 5a), whereas it was associated with lower expression levels of *CSF3* in CHB: Han Chinese in Beijing, China, in the probe of ILMN_1655639 ($\rho = -0.48$, $P = 5.5 \times 10^{-6}$) (Supplementary Fig. 5b), and in MEX in that of ILMN_1706852 ($\rho = -0.33$, $P = 0.028$) (Supplementary Fig. 5c).

CSF3 encodes a cytokine, known as G-CSF which is produced by different type of cells such as macrophages,

monocytes, stromal cells in the bone marrow, fibroblast, and endothelial cells. The eQTL analysis is based on the whole-genome gene expression variations in lymphoblastoid cell lines derived from HapMap individuals. Therefore, it was still necessary to analyze gene expression in G-CSF producing cells, as well as expression at the protein level. Hence, we measured serum G-CSF levels at baseline and week 2 or 4 (at the time of minimum neutrophil counts) in 127 CHC patients receiving IFN-based therapy. There were no differences in serum G-CSF levels at baseline and the time of minimum neutrophil counts as well as in their changes according to rs2305482 or rs4794822 genotypes (Supplementary Fig. 6a, b). In addition, neutrophil counts

Table 3 Association of SNPs located in *PSMD3-CSF3* with interferon-induced neutropenia

dbSNP rsID	Nearest gene	Risk allele	Allele (1/2)	Case-G2 + R ^a (n = 100)		Control-G + R ^b (n = 656)		OR ^c (95 % CI)	P value ^d
				11	12	11	12		
rs9915252	<i>PSMD3</i>	G	G/C	23 (24.0)	47 (49.0)	26 (27.1)	57 (8.9)	2.13 (1.57–2.89)	9.64×10^{-7}
rs4794822	<i>PSMD-CSF3</i>	C	C/T	42 (42.9)	45 (45.9)	11 (11.2)	130 (21.2)	2.24 (1.63–3.07)	3.63×10^{-7}
rs3907022	<i>GSDMA-PSMD</i>	A	A/G	41 (41.8)	45 (45.9)	12 (12.2)	129 (21.3)	2.11 (1.54–2.89)	2.31×10^{-6}
rs3859192	<i>GSDMA</i>	C	C/T	37 (37.8)	44 (44.9)	17 (17.3)	123 (19.9)	1.82 (1.34–2.48)	1.04×10^{-4}

Data of allele distribution represent number (%). Data of subjects whose genotypes were not determined were excluded

SNP single nucleotide polymorphism

^a Case-G2 + R: Case-G2 plus Case-R

^b Control-G + R: Control-G plus Control-R

^c Odds ratio for the allele frequency model

^d P value by the Chi square test for the allele frequency model

did not correlate with serum G-CSF levels at baseline and the time of minimum neutrophil counts (Supplementary Fig. 7a), and there was no difference in the changes of serum G-CSF levels from baseline to the time of minimum neutrophil counts between patients with minimum neutrophil counts of $\geq 1,000/\text{mm}^3$ and $<600/\text{mm}^3$ (Supplementary Fig. 7b).

Discussion

The present GWAS first showed a strong association between genetic variant and IFN-induced neutropenia, namely, with rs2305482 in *PSMD3* on chromosome 17. Although neutrophil counts at baseline were associated with the rs2305482 genotype and the incidence of neutropenia during IFN-based therapy, the logistic regression analysis revealed that the rs2305482 genotype was independently associated with IFN-induced neutropenia.

Intriguingly, the *PSMD3-CSF3* locus was reported to be associated with total white blood cell (WBC) counts based on GWAS of populations with European ancestry (Crosslin et al. 2012; Soranzo et al. 2009) and in Japanese (Kamatani et al. 2010). These findings were replicated in African Americans (Reiner et al. 2011). Moreover, another GWAS by Okada et al. (2010) showed that rs4794822 in *PSMD3-CSF3* was associated with neutrophil counts in 14 different groups of diseases in Japanese patients who were not undergoing chemotherapy. In the present study, rs4794822 as well as rs2305482 was also associated with pretreatment neutrophil counts in CHC patients (Supplementary Fig. 2). However, there have been no reports showing an association between *PSMD3-CSF3* variants and reduction of WBC or neutrophil counts following treatments such as IFN and chemotherapy. The pairwise LD diagram for *PSMD3-CSF3* by HapMap JPT shows that rs4794822 is in strong LD with rs2305482, which we identified here (Fig. 2). In the present study, both rs2305482 and rs4794822 were associated with IFN-induced neutropenia. Collectively, previous reports together with our results imply that the *PSMD3-CSF3* locus is associated with neutropenia in CHC patients under IFN-based therapy as well as with neutrophil counts in healthy individuals and patients without bone marrow suppressive therapy.

In further clinical investigation, the rs2305482 and rs4794822 genotypes were associated with the doses of PEG-IFN that could be given to HCV genotype 1-infected patients treated with PEG-IFN/RBV (Fig. 3; Supplementary Fig. 4). Unfortunately, we could not collect the detailed information about the reason for the reduction of PEG-IFN in this group. However, we highly suppose that these SNPs affected the doses of PEG-IFN through neutropenia in some cases, since neutropenia is one of the major

Table 4 Univariate analysis of pretreatment factors associated with interferon-induced neutropenia

	Case-G2 + R ^a (n = 100)	Control-G + R ^b (n = 656)	P value ^c
Gender, male/female	45/55	378/278	0.018
Age, years	58.1 (9.3)	56.9 (10.4)	0.262
Neutrophil count, /mm ³	1,614 (735)	2,742 (979)	<0.001
Hemoglobin, g/dL	13.5 (1.5)	14.2 (1.5)	<0.001
Platelet count, ×10 ⁹ /L	136 (46)	163 (57)	<0.001
ALT, IU/L	79.1 (69.7)	83.5 (74.3)	0.574
HCV RNA, log IU/ml	6.0 (0.9)	6.1 (0.8)	0.164
Liver fibrosis, F0-2/F3-4/ND	46/16/38	397/157/102	0.674
rs2305482, AA + AC/CC/ND	74/24/2	591/59/6	<0.001
rs4794822, TT + TC/CC/ND	56/42/2	484/130/42	<0.001

Data are expressed as number for categorical data or the mean (standard deviation) for non-categorical data

ALT alanine transaminase, ND not determined

^a Case-G2 + R: Case-G2 plus Case-R

^b Control-G + R: Control-G plus Control-R

^c Categorical variables were compared between groups by the Chi square test and non-categorical variables by the Student's *t* test

Table 5 Logistic regression analysis of pretreatment factors associated with interferon-induced neutropenia

	OR (95 % CI)	P value
Gender, female	1.229 (0.734–2.059)	0.4331
Neutrophil count, /mm ³	0.998 (0.997–0.998)	<0.0001
Platelet count, ×10 ⁹ /L	1.005 (0.953–1.059)	0.8604
rs2305482, CC	2.497 (1.281–4.864)	0.0072

reasons for the dose reduction of PEG-IFN in PEG-IFN/RBV therapy. While, there were no associations between SVR and rs2305482 or rs4794822 genotypes (Supplementary Table 3).

PSMD3 encodes the proteasome 26S subunit, non-ATPase 3, a member of the 26S proteasome family, and is involved in the control of cell cycle transition via the ubiquitin–proteasome pathway (Bailly and Reed 1999). *CSF3* encodes G-CSF, which controls the production, differentiation, and function of granulocytes (Nagata et al. 1986). Recombinant G-CSF is widely used to treat patients with severe neutropenia during chemotherapy. Therefore, we hypothesize that *PSMD3-CSF3* variants may influence neutrophil counts through affecting the process of endogenous G-CSF synthesis during IFN-based therapy or other bone marrow suppressive therapies. However, eQTL analysis by Okada et al. (2010) showed that rs4794822 was significantly associated with the expression level of *PSMD3*, rather than that of *CSF3* in the JPT and CHB populations. Our eQTL analysis showed that the risk allele for neutropenia at rs2305482 correlated with higher expression levels of *PSMD3* in LWK and MEX populations (Supplementary Fig. 5a), whereas with lower expression levels of *CSF3* in MEX and especially in CHB populations (Supplementary Fig. 5b, c). However, these results were not replicated in the other probe of *CSF3*. Additionally, we analyzed serum G-CSF levels in CHC patients receiving IFN-based therapy. Although serum G-CSF levels were thought to be increased in response to neutropenia regardless of rs2305482 and rs4794822 genotypes, there was no evidence that they were lower in patients with a risk allele of these SNPs at baseline and during the neutropenic period (Supplementary Fig. 6). Moreover, neutrophil counts did not correlate with serum




Fig. 3 Administered doses of PEG-IFN and RBV according to rs2305482 genotypes. The patients were stratified into three groups according to the doses of PEG-IFN or RBV administered, as follows: <60 %, ≥60 to <80 %, ≥80 % of the planned doses for 48 weeks. The proportion of patients receiving <60 % of the PEG-IFN doses was significantly higher in patients with rs2305482 CC than in those with AA/AC ($P = 0.005$, by the Chi square test). *PEG-IFN* pegylated interferon, *RBV* ribavirin

G-CSF levels at baseline and the time of minimum neutrophil counts (Supplementary Fig. 7a). Further functional analyses of these genes and polymorphisms are required to elucidate the reason for the association between *PSMD3-CSF3* and IFN-induced neutropenia as well as neutrophil counts in healthy individuals.

In previous reports, *PLBC4*, *DARC*, *CXCL2*, and *CDK5* loci have also been associated with neutrophil or WBC counts in healthy individuals or patients who were not under chemotherapy (Crosslin et al. 2012; Kamatani et al. 2010; Okada et al. 2010; Reiner et al. 2011). However, there were no associations with these loci discernible in our GWAS.

The important limitation of this study is that the association between rs2305482 and IFN-induced neutropenia was not statistically significant in a genome-wide level. Thompson et al. (2012) also identified no genetic determinants of IFN-induced neutropenia during PEG-IFN/RBV therapy at the level of genome-wide significance by their GWAS. Unlike our study design, they analyzed the association between the reduction of neutrophil counts at week 4 and any SNPs. Indeed, we analyzed the association between the reduction of neutrophil counts at week 2 or 4 and rs2305482 or rs4794822, but there was no significant association. Therefore, further independent replication analyses which are designed in the similar way as our study are desirable.

IFN-free therapies are expected to be useful especially in IFN-resistant patients and may become the standard of care in the near future. However, combination therapies of DAA and IFN will continue to be used for some time. Our findings contribute to our understanding of the genetic factors influencing IFN-induced neutropenia. Furthermore, these genetic variants may be associated with neutropenia during chemotherapies for various malignant diseases as well as IFN-based therapy for CHC. Therefore, genetic testing of these variants might be useful for establishing personalized doses of such therapies to minimize drug-induced adverse events. Additionally, our results might contribute to the elucidation of the mechanism of drug-induced neutropenia.

Acknowledgments We thank Ms. Yasuka Uehara-Shibata, Yuko Ogasawara-Hirano, Yoshimi Ishibashi, Natsumi Baba, Megumi Yamakawa-Sageshima, Takayo Tsuchiura, Yoriko Mawatari (Tokyo University), and Dr. Shintaro Ogawa (Nagoya City University) for technical assistance. This work was supported by the Ministry of Health, Labor, and Welfare of Japan (H25-kanen-ippan-005) to Yasuhito Tanka and Katsushi Tokunaga, KAKENHI (22133008) Grant-in-Aid for Scientific Research on Innovative Areas to Katsushi Tokunaga, and KAKENHI (24790728) Grant-in-Aid from the Ministry of Education, Culture, Sports, Science of Japan for Young Scientists (B) to Nao Nishida.

Conflict of interest The following authors are currently conducting research sponsored by the companies: Yasuhito Tanaka, Keisuke Hino,

and Yoshito Itoh by Merck Sharp & Dohme, Corp., Chugai Pharmaceutical Co., Ltd., and Bristol-Myers Squibb; Nobuyuki Enomoto, Shuhei Nishiguchi, and Eiji Tanaka by Merck Sharp & Dohme, Corp. and Chugai Pharmaceutical Co., Ltd.; Naoya Sakamoto by Chugai Pharmaceutical Co., Ltd, Bristol-Myers Squibb, Merck Sharp & Dohme, Corp., and Otsuka Pharmaceutical Co., Ltd.; Hiroshi Yatsushashi by Chugai Pharmaceutical Co., Ltd.; Akihiro Tamori by Merck Sharp & Dohme, Corp.; Satoshi Mochida by Merck Sharp & Dohme, Corp., Chugai Pharmaceutical Co., Ltd., Bristol-Myers Squibb, and Toray Medical Co., Ltd. The other authors have no conflict of interest.

Compliance with ethical standards All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

Informed consent Informed consent was obtained from all individual participants included in the study.

References

- Bailly E, Reed SI (1999) Functional characterization of *rpn3* uncovers a distinct 19S proteasomal subunit requirement for ubiquitin-dependent proteolysis of cell cycle regulatory proteins in budding yeast. *Mol Cell Biol* 19:6872–6890
- Crosslin DR, McDavid A, Weston N, Nelson SC, Zheng X, Hart E, de Andrade M, Kullo IJ, McCarty CA, Doheny KF, Pugh E, Kho A, Hayes MG, Pretel S, Saip A, Ritchie MD, Crawford DC, Crane PK, Newton K, Li R, Mirel DB, Crenshaw A, Larson EB, Carlson CS, Jarvik GP (2012) Genetic variants associated with the white blood cell count in 13,923 subjects in the eMERGE Network. *Hum Genet* 131:639–652. doi:10.1007/s00439-011-1103-9
- Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulkowski M, McHutchison JG, Goldstein DB (2010) ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature* 464:405–408. doi:10.1038/nature08825
- Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 461:399–401. doi:10.1038/nature08309
- George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM (2009) Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. *Hepatology* 49:729–738. doi:10.1002/hep.22694
- Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 364:2405–2416. doi:10.1056/NEJMoa1012912
- Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y, Nakamura Y, Kamatani N (2010) Genome-wide association study of hematological and biochemical traits in a Japanese population. *Nat Genet* 42:210–215. doi:10.1038/ng.531
- Kurosaki M, Tanaka Y, Tanaka K, Suzuki Y, Hoshioka Y, Tamaki N, Kato T, Yasui Y, Hosokawa T, Ueda K, Tsuchiya K, Kuzuya T,